Literature DB >> 7940435

Atrial natriuretic peptide levels in the sleep apnoea/hypopnoea syndrome.

T W Mackay1, M F Fitzpatrick, S Freestone, M R Lee, N J Douglas.   

Abstract

BACKGROUND: Patients with the sleep apnoea/hypopnoea syndrome have increased salt and water excretion at night which has been reported to be associated with an increase in plasma levels of atrial natriuretic peptide (ANP). A study was performed to determine whether any rise in plasma ANP levels was related to nocturnal hypoxaemia.
METHODS: Nine patients with sleep apnoea/hypopnoea syndrome were studied on two nights, one breathing air and the other 28% oxygen, the order being randomised. Venous levels of ANP, aldosterone, and renin activity were measured.
RESULTS: No decrease in plasma ANP levels on oxygen was seen, and, indeed, there was no evidence of an overnight increase in ANP levels.
CONCLUSION: Oxygen therapy does not diminish nocturnal plasma ANP levels in patients with sleep apnoea/hypopnoea syndrome.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7940435      PMCID： PMC475196          DOI： 10.1136/thx.49.9.920

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  15 in total

1.  Atrial natriuretic peptide and catecholamines in obstructive sleep apnea syndrome.

Authors:  A Baruzzi; R Riva; F Cirignotta; M Zucconi; M Cappelli; E Lugaresi
Journal:  Sleep       Date:  1991-02       Impact factor: 5.849

2.  Clinical features of the sleep apnoea/hypopnoea syndrome.

Authors:  K F Whyte; M B Allen; A A Jeffrey; G A Gould; N J Douglas
Journal:  Q J Med       Date:  1989-07

3.  Atrial natriuretic peptide release during sleep in patients with obstructive sleep apnoea before and during treatment with nasal continuous positive airway pressure.

Authors:  J Krieger; L Laks; I Wilcox; R R Grunstein; L J Costas; J G McDougall; C E Sullivan
Journal:  Clin Sci (Lond)       Date:  1989-10       Impact factor: 6.124

4.  Abnormal diurnal variation in salt and water excretion in patients with obstructive sleep apnoea.

Authors:  A R Warley; J R Stradling
Journal:  Clin Sci (Lond)       Date:  1988-02       Impact factor: 6.124

5.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

6.  Urinary excretion of guanosine 3':5'-cyclic monophosphate during sleep in obstructive sleep apnoea patients with and without nasal continuous positive airway pressure treatment.

Authors:  J Krieger; M Schmidt; E Sforza; L Lehr; J L Imbs; G Coumaros; D Kurtz
Journal:  Clin Sci (Lond)       Date:  1989-01       Impact factor: 6.124

7.  Factors impairing daytime performance in patients with sleep apnea/hypopnea syndrome.

Authors:  K Cheshire; H Engleman; I Deary; C Shapiro; N J Douglas
Journal:  Arch Intern Med       Date:  1992-03

8.  Renal function in patients with obstructive sleep apnea. Effects of nasal continuous positive airway pressure.

Authors:  J Krieger; J L Imbs; M Schmidt; D Kurtz
Journal:  Arch Intern Med       Date:  1988-06

9.  Clinical value of polysomnography.

Authors:  N J Douglas; S Thomas; M A Jan
Journal:  Lancet       Date:  1992-02-08       Impact factor: 79.321

10.  Atrial natriuretic peptide in habitual snorers.

Authors:  M Partinen; T Telakivi; A Kaukiainen; T Salmi; M Färkkilä; O Saijonmaa; F Fyhrquist
Journal:  Ann Med       Date:  1991-04       Impact factor: 4.709
View more
  1 in total

1.  Copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea-a prospective intervention study.

Authors:  Meropi Karakioulaki; Peter Grendelmeier; Werner Strobel; Thomas Schmid; Kathleen Jahn; Leticia Grize; Michael Tamm; Daiana Stolz
Journal:  Respir Res       Date:  2021-04-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.